Download App

Log in to access Online Inquiry
Company Overview More
Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals dedicated to the discovery or licensing, development and commercialization of proprietary therapies to address a large number of unmet medical needs in the Chinese market, including oncology, autoimmunity and infectious diseases. The company has a range of patent candidates from the discovery phase to the later stages of the clinical program. It includes Niraparib (ZL-2306), ZL-2103, ZL-1101 and so on.
CEO: Ying Du
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

09688 ZAI LAB-SB
29.000-0.150-0.51%
YOY
Do not show
Hide blank lines
(Q3)2022/03/31(FY)2021/12/31(Q9)2021/09/30(Q6)2021/06/30
Assets
Current assets
Inventory
60.65% 20.29M 44.18% 18.95M -- 12.49M 69.19% 11.11M
Accounts receivable
278.83% 33.39M 819.15% 47.47M -- 21.02M 156.68% 18.03M
Notes receivable
-- 10.85M -- 7.34M -- -- -- --
Advance deposits and other receivables
15.15% 16.49M 64.8% 18.02M -- 17.08M 67.71% 12.89M
Cash and equivalents
-16.43% 846.96M 118.06% 964.1M -- 1.4B 583.12% 1.77B
Short-term investment
-- 465.27M -40.24% 445M -- 170M -- --
Total current assets
32.79% 1.39B 23.42% 1.5B -- 1.62B 273% 1.81B
Non-current assets
Property, plant and equipment
55.87% 45.23M 47.8% 43.1M -- 37.09M 50.55% 31.64M
Land use right
-0.13% 7.77M -1.23% 7.81M -- 7.75M 5.84% 7.85M
Advance payment
1940.16% 4.98M 63.64% 1.86M -- -- 381.98% 1.85M
long-term investment
-- 8.44M -- -- -- -- -- --
Other investments
-- -- 1120.09% 15.61M -- -- -- --
Intangible assets
10.09% 1.75M 20.63% 1.85M -- 1.68M 42.52% 1.73M
Special items of non-current assets
-9.15% 39.5M -4.27% 38.85M -- 62.48M 39.07% 43.54M
Total non-current assets
31.13% 107.66M 33.67% 109.08M -- 108.99M 36.76% 86.61M
Total assets
32.67% 1.5B 24.07% 1.61B -- 1.73B 245.71% 1.9B
Liabilities
Current liabilities
Accounts payable
137.02% 98.16M 101.41% 126.16M -- 51.41M 287.81% 125.62M
Other current liabilities
9.46% 49.96M 101.39% 60.81M -- 54.29M 293.17% 61.93M
Special items of current liabilities
21.3% 6.8M 13.85% 5.93M -- 6.31M 52.6% 6.37M
Total current liabilities
67.19% 154.91M 96.75% 192.9M -- 112.01M 242.88% 193.92M
Net current assets
29.46% 1.24B 16.99% 1.31B -- 1.51B 276.98% 1.61B
Total assets less current liabilities
29.59% 1.35B 18.13% 1.42B -- 1.62B 246.03% 1.7B
Non-current liabilities
Deferred income-non-current liabilities
61.47% 26.9M 63.04% 27.49M -- 17.49M 12.05% 17.63M
Special items of non-current liabilities
-9.82% 11.1M -28.22% 9.61M -- 10.65M 14.45% 11.97M
Total non-current liabilities
31.18% 38M 22.64% 37.1M -- 28.14M 13.01% 29.6M
Total liabilities
58.61% 192.91M 79.28% 230M -- 140.15M 170.12% 223.52M
Total assets less total liabilities
29.55% 1.31B 18.01% 1.38B -- 1.59B 259.15% 1.67B
Total equity and non-current liabilities
29.59% 1.35B 18.13% 1.42B -- 1.62B 246.03% 1.7B
Equity
Share capital
20% 6K 20% 6K -- 6K 50% 6K
Retained profit
-58.53% -1.5B -98.72% -1.42B -- -1.21B -93.58% -1.11B
Special items of shareholders' rights and interests
43.57% 2.81B 48.6% 2.8B -- 2.79B 167.77% 2.78B
Shareholders' Equity
29.55% 1.31B 18.01% 1.38B -- 1.59B 259.15% 1.67B
Total equity
29.55% 1.31B 18.01% 1.38B -- 1.59B 259.15% 1.67B
Total equity and total liabilities
32.67% 1.5B 24.07% 1.61B -- 1.73B 245.71% 1.9B
Currency Unit
USDUSDUSDUSD
Accounting Standards
UASUASUASUAS
Audit Opinions
--Unqualified Opinion----
Auditor
--Deloitte Guan Huang Chen Fang Accountants----

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%